CAR T Cell Therapy Segment Held Largest Share of Product Segment in T Cell Therapy Market

According to our latest study on " T Cell Therapy Market Size and Forecast to 2030 – COVID-19 Impact and Global Analysis – by Type, Application, and Purchase Mode," the T cell therapy market size was valued at US$ 2,754.0 million in 2022 and is expected to reach US$ 9,035.01 million by 2030. It is estimated to register a CAGR of 16.0% during 2022–2030. The report highlights the key factors and trends impacting the market and focuses on prominent players and their strategies.

T-cell transfer therapy is a type of immunotherapy that makes immune cells better able to attack cancer. There are two main types of T-cell transfer therapy: T-cell therapy receptor (TCR) therapy and CAR T-cell therapy. Both are involved in collecting immune cells, grown in large numbers in the lab, and then intravenously delivered to the patient. T-cell transfer therapy is also called adoptive cell therapy, adoptive immunotherapy, and immune cell therapy.

Companies operating in the T cell therapy market focus on strategic developments such as collaborations, expansions, agreements, and investment, which help them improve their sales, expand their geographic reach, and enhance their capacities to cater to a larger than existing customer base. A few noteworthy developments in the T cell therapy market are mentioned below.

• In August 2023, Astellas invested US$ 50 million in Poseida’s CAR T-cell therapy. Astellas will have exclusive negotiation and first refusal for licensing P-MUC1C-ALLO1 in solid tumors as part of the agreement. P-MUC1C-ALLO1 is an allogeneic CAR T-cell therapy targeting cancer-specific Mucin 1 protein (MUC1-C) forms. It is currently under investigation in an open-label multicentre Phase I clinical trial (NCT05239143) treating multiple epithelial-derived solid tumor indications.
• In May 2023, Laurus Labs’ stake in ImmunoACT will now increase to 33.86% on a fully diluted basis post completion of the deal. The company had already acquired 26.62% of stakes in ImmunoACT in November 2021. ImmunoACT has a portfolio of CAR T-cell therapy assets under various development stages for treating multiple autoimmune diseases and oncology indications. This investment further strengthens Laurus Labs’ commitment to accessing novel Cell and Gene Therapy technology and enhances its affordability for patients. This investment will further help ImmunoACT to gear up for the manufacture of more treatments.
• In January 2023, the California Institute for Regenerative Medicine (CIRM) invested US$ 4 million to develop and test a CAR T-cell therapy to treat various B-cell malignancies, ranging from lymphomas to leukemias.
• In November 2021, Autolus Therapeutics plc (a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies) and Blackstone Life Sciences entered into a strategic collaboration and financing agreement under which funds managed by Blackstone will provide up to US$ 250 million in equity and product financing to support Autolus’ advancement of its CD19 CAR T cell investigational therapy product candidate, obecabtagene autoleucel (obe-cel), as well as the next-generation product therapies of obe-cel in B-cell malignancies.

Thus, these investments create lucrative opportunities in the T cell therapy market.

Immunocore Holdings PLC, Legend Biotech Corp, Janssen Global Services LLC, Gilead Sciences Inc, Bristol Myers Squibb Co, Bluebird Bio Inc, Novartis AG, JW (Cayman) Therapeutics Co Ltd, Cartesian Therapeutics, and Innovent Biologics are among the key players operating in the global T cell therapy market.

The report segments the global T cell therapy market as follows:

The T cell therapy market is segmented into modality, therapy type, indication, and geography. By modality, the T cell therapy market is bifurcated into research and commercialized. Based on therapy type, the T cell therapy market is segmented into CAR T-cell therapy and T-cell receptor (TCR)-based. Based on indication, the T cell therapy market is segmented into hematologic malignancies and solid tumors. Geographically, the T cell therapy market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, Israel, and Rest of Middle East & Africa), and South & Central America (Brazil).

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com